TrialCard in the Media
Paul LeVine, VP for analytic services at TrialCard, highlights ways in which co-pay programs and ancillary services can go beyond addressing the price of medications.
Co-pay savings programs drive new patient starts and promote continued adherence, but their effectiveness eventually reaches a “leveling off” point. This webcast examines how adding an outbound virtual engagement solution enabled a top allergy brand overcome this type of program plateau to continue achieving strong brand performance.
TrialCard’s VP of Healthcare Professional Engagement, Michael Carlin, weighs in on strategies to overcome the challenges with marketing products indicated for rare diseases.
TrialCard shares its approaches for modeling which patients are at risk for poor adherence, and how to identify the interventions that can best improve patients’ medication-taking behavior.
Larry Dobrow, senior editor of MM&M, speaks with Robert Leedom, senior analytics consultant at TrialCard, and Paul LeVine, VP of analytic services for TrialCard, about how to reach patients by leveraging brand data.
TrialCard’s Paul LeVine, VP of Analytic Services, weighs in on the idea of a HUB as a vehicle that can provide solutions to the challenge of showing improved patient outcomes.
In this episode, Michael Carlin of TrialCard discusses rare diseases and orphan drugs, and how life sciences companies can overcome the many business challenges associated with these types of disease states.
Marc Iskowitz, MM&M’s editor in chief, discusses a qualitative/quantitative approach to meeting orphan drug marketers’ engagement challenge with Michael Carlin, VP of virtual engagement at TrialCard.